ClinicalTrials.gg
TerminatedNCT02294786Updated Jul 15, 2019Results posted

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

A Phase 2 interventional study of Lapatinib and Capecitabine in Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 17 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-15.

Primary conditionBreast NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Breast Neoplasms
Why
  1. The study's title name Breast Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies testing lapatinib in Breast Neoplasms — none open to participants now, 3 under way, 1 of them phase 3. Lapatinib · Breast Neoplasms.

Enrollment
38th of 114
62 · median 35
Started
2014
with 3 others
Phase 2
60 of 114
none open now
Registered
112th of 114
by date
Lead sponsor
15 of 114
Novartis Pharmaceuticals

Among the 114 studies testing lapatinib in Breast Neoplasms, this one is the 38th largest by enrollment, is one of 4 that started in 2014, is one of 60 in phase 2, and was the 112th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 114 studies testing lapatinib in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About lapatinib

Lapatinib: first FDA approval 2007 (TYKERB), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 114 studies testing lapatinib in Breast Neoplasms as a file.
02

Study summary

Diarrhoea is the most commonly reported adverse event (AE) associated with Lapatinib treatment, and is also commonly associated with Capecitabine treatment. Although these events are generally mild to moderate in severity, diarrhoea adversely affects the tolerability of cancer treatment, and in severe cases diarrhoea has the potential to affect the efficacy of treatment due to poor compliance, or treatment interruption or withdrawal. The efficacy of Octreotide in the management of cancer treatment-associated diarrhoea has not been extensively evaluated in large, well-controlled studies. This is a randomised, multi-centre, open-label Phase II study in subjects with Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer which has progressed following prior therapy, which must have included anthracyclines and taxanes and therapy with Trastuzumab in the metastatic setting. This study is not placebo controlled, and there is no active comparator. The study evaluates whether the prophylactic use of Octreotide Long Acting Release (LAR) offers a clinically meaningful benefit by reducing the frequency and severity of diarrhoea associated with treatment with Lapatinib and Capecitabine. Study completion for a subject is defined as the completion of 24 weeks of treatment with Lapatinib and Capecitabine, or progression of cancer or the death of the subject during treatment, whichever occurs first. Approximately 140 subjects were planned to be randomized out of which 70 were planned to receive octreotide and 70 were planned to receive no Octreotide.

03

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Randomised
  • Octreotide
  • Diarrhoea
  • Phase II
  • Capecitabine
  • Quality of life
  • Metastatic breast cancer
  • HER2
  • Lapatinib
  • Diarrhoea diary
04

In context

Breast Neoplasms Reclassified

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 62 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • or cytologically confirmed -positive advanced or breast cancer which has progressed following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting
  • Females age >=18 years old
  • (ECOG) performance status 0-2
  • of at least 12 weeks
  • Able to swallow and retain oral medications
  • Incapable of becoming pregnant, or not pregnant and using an adequate form of , i.e. a female who is of:

    1. non- (physiologically incapable of becoming pregnant), including any female who has had hysterectomy, bilateral oophorectomy, bilateral tubular ligation or is (total cessation of menses for at least 1 year);
    2. childbearing potential must have a negative serum pregnancy test within 7 days prior to treatment with Octreotide if randomised to receive Octreotide or the first dose of Lapatinib with Capecitabine if randomised to receive no Octreotide, preferably as close to the first dose as possible, and must agree to use adequate contraception (intrauterine device, birth control pills unless clinically , or barrier device) and other acceptable contraceptive methods during the study and continuing for at least 4 weeks after the final dose of treatment with Lapatinib and Capecitabine
  • Subjects must complete all screening assessments as outlined in the protocol
  • Subjects must complete the Functional Assessment of Chronic Illness Therapy-Diarrhoea (FACIT-D) and diarrhoea diary before receiving the first dose of Octreotide if randomised to receive Octreotide. All subjects must complete the FACIT-D and diarrhoea diary before receiving the first dose of Lapatinib with Capecitabine
  • Prior treatment with other chemotherapeutic agents or endocrine therapy is permitted. All prior treatment related toxicities, except diarrhoea and alopecia, must be National Cancer Institute (NCI CTCAE) (version 4.03)\<= Grade 1 at the time of randomization.Subjects with diarrhoea with any grade of severity within 14 days prior to randomisation are excluded from LAP117314
  • Prior treatment with radiation therapy is permitted provided that at least 2 weeks have elapsed since the last fraction of radiation therapy prior to treatment with Octreotide if randomised to receive Octreotide or the first dose of Lapatinib with Capecitabine if randomised to receive no Octreotide, and all radiation therapy related AEs are \<= Grade 1 at the time of randomization
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category

Exclusion criteria

Exclusion Criteria:

  • Concurrent treatment with an agent or concurrent participation in another clinical study
  • Administration of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to treatment with Octreotide for subjects randomised to receive Octreotide or the first dose of Lapatinib and Capecitabine for subjects randomised to receive no Octreotide
  • Treatment with Octreotide within the 3 months prior to randomization
  • Concurrent chemotherapy, radiation therapy, immunotherapy, biologic therapy (including an Epidermal growth factor receptor (EGFR) and/or inhibitor), or hormonal therapy for treatment of cancer
  • Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of , unless a legally acceptable representative could provide informed consent (if in accordance with the policies of the local Ethics Committee)
  • Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the subject's safety or compliance with study procedures
  • Diarrhoea with any grade of severity within 14 days prior to treatment with Octreotide for subjects randomised to receive Octreotide or within 14 days prior to the first dose of Lapatinib and Capecitabine for subjects randomised to receive no Octreotide
  • Malabsorption syndrome, inflammatory bowel disease (ulcerative colitis, Chrohn's disease), irritable bowel syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel
  • Pregnant or lactating subjects
  • Prior treatment with Lapatinib
  • French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days or 5 half-lives, whichever is longer, preceding the first dose of protocol treatment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Octreotide treatment

    Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m\^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.

    Drug: Lapatinib · Drug: Capecitabine · Drug: Octreotide

  • Experimental
    No Octreotide treatment

    Subjects randomised to receive no octreotide, treatment with Lapatinib and Capecitabine was initiated immediately following enrolment. All subjects received treatment with Lapatinib 1250mg once daily and Capecitabine 1000mg/m\^2 twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment

    Drug: Lapatinib · Drug: Capecitabine

Interventions

  • Lapatinib was supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contained 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base

  • Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.

  • Octreotide (Sandostatin LAR™) was supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections were given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol was added to the microspheres to improve suspendability

07

What researchers measure

Primary outcomes

  1. Proportion of Subjects Experiencing Diarrhoea of Grade 2 and Above (up to 24 Weeks)

    Proportion of subjects experiencing at least one episode of diarrhoea with a severity of Grade 2 and above, as defined by the National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) version 4.03, recorded as AEs in the Electronic case report form (eCRF)

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Proportion of Subjects Experiencing Diarrhoea of Grade 3 and Above (up to 24 Weeks)

    Proportion of subjects experiencing diarrhoea with a severity of Grade 3 and above, as defined by the NCI CTCAE, version 4.03 and recorded as AEs in the eCRF

    Time frame: Up to 24 weeks

  2. Proportion of Subjects Experiencing Diarrhoea of Any Grade of Severity (up to 24 Weeks)

    Proportion of subjects experiencing diarrhoea of any grade of severity as defined by the NCI CTCAE, version 4.03 and recorded as AEs in the eCRF

    Time frame: Up to 24 weeks

  3. Duration of Diarrhoea of Any Grade of Severity

    Duration of diarrhoea of any grade of severity, recorded as AEs in the eCRF

    Time frame: Up to 24 weeks

  4. Time to Onset of the First Episode of Diarrhoea of Any Grade of Severity

    Time to onset of the first episode of diarrhoea of any grade of severity, recorded as an AE in the eCRF. Subject are censored if there was no event. Median time and 95% confidence intervals were calculated using Kaplan-Meier estimates.

    Time frame: Up to 24 weeks

  5. Proportion of Subjects Taking Anti-diarrhoeal Medication

    Proportion of subjects taking anti-diarrhoeal medication as recorded in the eCRF

    Time frame: Up to 24 weeks

  6. Proportion of Subjects Who Had Unscheduled Visits to Healthcare Professionals Due to Diarrhoea

    Proportion of subjects making diarrhoea related unscheduled visits to healthcare professionals as recorded in the eCRF

    Time frame: Up to 24 weeks

  7. Proportion of Subjects Requiring Dose Reduction in Lapatinib and Capecitabine

    Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine dose reduction as recorded in the eCRF

    Time frame: Up to 24 weeks

  8. Proportion of Subjects Requiring Dose Delay in Lapatinib and Capecitabine

    Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine dose delay as recorded in the eCRF

    Time frame: Up to 24 weeks

  9. Proportion of Subjects Requiring Treatment Withdrawal in Lapatinib and Capecitabine

    Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine treatment withdrawal as recorded in the eCRF

    Time frame: Up to 24 weeks

  10. Proportion of Subjects Requiring Use of Diarrhoea-related Intravenous Fluids

    Proportion of subjects requiring use of diarrhoea-related intravenous fluids for rehydration as recorded in the eCRF

    Time frame: Up to 24 weeks

  11. Number of Lapatinib and Capecitabine Tablets Dispensed and Returned

    Number of Lapatinib and Capecitabine tablets dispensed and returned as recorded in the eCRF

    Time frame: Up to 24 weeks

  12. Overall Response Rate (up to 24 Weeks)

    Overall response rate as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>=20% and \>= 5mm increase in the sum of diameters of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Up to 24 weeks

  13. Clinical Benefit Response (up to 24 Weeks)

    Clinical benefit response as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Clinical Benefit Response rate (CBR) is defined as the percentage of subjects with a CR, PR or SD at week 24.

    Time frame: Up to 24 weeks

  14. Proportion of Subjects Reporting Changes in Bowel Movements From Baseline (Frequency and/or Consistency) as Recorded in the Diarrhoea Management Diary (DMD)

    All subjects completed the baseline DMD during the 3 days prior to randomisation, before any study-related treatment is administered. Subjects randomised to receive Octreotide completed a second baseline DMD before starting the first cycle of treatment with Lapatinib and Capecitabine. The baseline DMD comprised of 3 questions to record stool form and consistency. The DMD to be completed throughout the rest of the study comprised of 3 questions in the baseline DMD and a further 5 questions and 6 sub-questions to evaluate the consequences and management of diarrhoea.

    Time frame: Up to 24 weeks

  15. Time to the First Subject Reported Change in Frequency and/or Consistency of Bowel Movements From Baseline as Recorded in the DMD

    Event is defined as Subjects reporting change in frequency and/or consistency of bowel movements from baseline at least once in DMD. Subject are censored if there is no change in bowel movement frequency/consistency as compared to baseline. Median time and 95% confidence intervals were calculated using Kaplan-Meier estimates.

    Time frame: Up to 24 weeks

  16. Proportion of Subjects Taking Anti-diarrhoeal Medication as Recorded in the DMD

    The proportion of subjects taking medication at least once as a result of diarrhoea are summarised

    Time frame: Up to 24 weeks

  17. Proportion of Subjects Making Dietary Changes Due to Diarrhoea as Recorded in the DMD

    The proportion of subjects making dietary changes to help with the diarrhoea are summarised

    Time frame: Up to 24 weeks

  18. Proportion of Subjects Contacting Other Non-hospital Healthcare Professionals to Discuss Diarrhoea as Recorded in the DMD

    The proportion of subjects contacting a health care professional other than the hospital doctors/nurses to discuss diarrhoea are summarised

    Time frame: Up to 24 weeks

  19. Proportion of Subjects Reporting Stopping Completely or Missing Doses of Anti-cancer Tablets Due to Diarrhoea as Recorded in the DMD

    The proportion of subjects reducing or completely stopping the number of anti-cancer tablets to help with diarrhoea are summarised

    Time frame: Up to 24 weeks

08

Results

Posted Jul 15, 2019

Participant flow

The study enrolled 62 women in 17 centers; Czech Republic (1), Israel (1), Poland (3), the United Kingdom (4) Russian Federation (8)

Participant flow — Overall Study
MilestoneOctreotide TreatmentNo Octreotide Treatment
Started3032
Safety population2933
Itt population3032
Completed1918
Not completed1114
Withdrew: Withdrawal by subject01
Withdrew: Physician decision67
Withdrew: Lost to follow-up12
Withdrew: Protocol violation10
Withdrew: Adverse event11
Withdrew: Death23

Outcome measures

PrimaryProportion of Subjects Experiencing Diarrhoea of Grade 2 and Above (up to 24 Weeks)

Proportion of subjects experiencing at least one episode of diarrhoea with a severity of Grade 2 and above, as defined by the National Cancer Institute common terminology criteria for adverse events (NCI CTCAE) version 4.03, recorded as AEs in the Electronic case report form (eCRF)

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Experiencing Diarrhoea of Grade 2 and Above (up to 24 Weeks)
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Cyclce 1-3 (up to 9 weeks)with impuation79
Cyclce 1-8 (up to 24 weeks)without imputation65
Statistical analysis
  • Octreotide Treatment vs No Octreotide Treatment · Chi-squared · p = 0.775 · Difference in percentages: -4.8 · 95% CI -29.2 to 20.0
SecondaryProportion of Subjects Experiencing Diarrhoea of Grade 3 and Above (up to 24 Weeks)

Proportion of subjects experiencing diarrhoea with a severity of Grade 3 and above, as defined by the NCI CTCAE, version 4.03 and recorded as AEs in the eCRF

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Experiencing Diarrhoea of Grade 3 and Above (up to 24 Weeks)
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Proportion of Subjects Experiencing Diarrhoea of Grade 3 and Above (up to 24 Weeks)20
SecondaryProportion of Subjects Experiencing Diarrhoea of Any Grade of Severity (up to 24 Weeks)

Proportion of subjects experiencing diarrhoea of any grade of severity as defined by the NCI CTCAE, version 4.03 and recorded as AEs in the eCRF

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Experiencing Diarrhoea of Any Grade of Severity (up to 24 Weeks)
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Proportion of Subjects Experiencing Diarrhoea of Any Grade of Severity (up to 24 Weeks)1814
SecondaryDuration of Diarrhoea of Any Grade of Severity

Duration of diarrhoea of any grade of severity, recorded as AEs in the eCRF

Time frame:
Up to 24 weeks
Reported as:
Mean · days
Duration of Diarrhoea of Any Grade of Severity
daysOctreotide TreatmentNo Octreotide Treatment
Duration of Diarrhoea of Any Grade of Severity8.7 ± 11.1536.8 ± 48.59
SecondaryTime to Onset of the First Episode of Diarrhoea of Any Grade of Severity

Time to onset of the first episode of diarrhoea of any grade of severity, recorded as an AE in the eCRF. Subject are censored if there was no event. Median time and 95% confidence intervals were calculated using Kaplan-Meier estimates.

Time frame:
Up to 24 weeks
Reported as:
Median · Days
Time to Onset of the First Episode of Diarrhoea of Any Grade of Severity
DaysOctreotide TreatmentNo Octreotide Treatment
Time to Onset of the First Episode of Diarrhoea of Any Grade of SeverityNA (54.0 to NA)170 (104 to NA)
SecondaryProportion of Subjects Taking Anti-diarrhoeal Medication

Proportion of subjects taking anti-diarrhoeal medication as recorded in the eCRF

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Taking Anti-diarrhoeal Medication
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Proportion of Subjects Taking Anti-diarrhoeal Medication711
SecondaryProportion of Subjects Who Had Unscheduled Visits to Healthcare Professionals Due to Diarrhoea

Proportion of subjects making diarrhoea related unscheduled visits to healthcare professionals as recorded in the eCRF

Time frame:
Up to 24 weeks

No measurements were reported for this outcome.

SecondaryProportion of Subjects Requiring Dose Reduction in Lapatinib and Capecitabine

Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine dose reduction as recorded in the eCRF

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Requiring Dose Reduction in Lapatinib and Capecitabine
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Subjects requiring dose reduction in Lapatinib10
Subjects requiring dose reduction in Capecitabine12
SecondaryProportion of Subjects Requiring Dose Delay in Lapatinib and Capecitabine

Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine dose delay as recorded in the eCRF

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Requiring Dose Delay in Lapatinib and Capecitabine
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Subjects requiring dose delay in Lapatinib22
Subjects requiring dose delay in Capecitabine22
SecondaryProportion of Subjects Requiring Treatment Withdrawal in Lapatinib and Capecitabine

Proportion of subjects requiring diarrhoea related Lapatinib and Capecitabine treatment withdrawal as recorded in the eCRF

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Requiring Treatment Withdrawal in Lapatinib and Capecitabine
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Requiring treatment withdrawal in Lapatinib00
Requiring treatment withdrawal in Capecitabine00
SecondaryProportion of Subjects Requiring Use of Diarrhoea-related Intravenous Fluids

Proportion of subjects requiring use of diarrhoea-related intravenous fluids for rehydration as recorded in the eCRF

Time frame:
Up to 24 weeks

No measurements were reported for this outcome.

SecondaryNumber of Lapatinib and Capecitabine Tablets Dispensed and Returned

Number of Lapatinib and Capecitabine tablets dispensed and returned as recorded in the eCRF

Time frame:
Up to 24 weeks
Reported as:
Mean · tablets
Number of Lapatinib and Capecitabine Tablets Dispensed and Returned
tabletsOctreotide TreatmentNo Octreotide Treatment
Number of Lapatinib tablets dispensed1197.5 ± 403.121115.6 ± 495.9
Number of Lapatinib tablets returned477.1 ± 173.94403.3 ± 238.47
Number of Capecitabine tablets dispensed1022.6 ± 473.441011.2 ± 532.06
Number of Capecitabine tablets returned186.1 ± 157.19210 ± 196.64
SecondaryOverall Response Rate (up to 24 Weeks)

Overall response rate as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>=20% and \>= 5mm increase in the sum of diameters of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Overall Response Rate (up to 24 Weeks)
ParticipantsOctreotide TreatmentNo Octreotide Treatment
complete response (CR)02
partial response (PR)64
stable disease (SD)45
Progressive Disease1417
Not Evaluable64
SecondaryClinical Benefit Response (up to 24 Weeks)

Clinical benefit response as measured in accordance with the Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Clinical Benefit Response rate (CBR) is defined as the percentage of subjects with a CR, PR or SD at week 24.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Clinical Benefit Response (up to 24 Weeks)
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Clinical Benefit Response (up to 24 Weeks)79
SecondaryProportion of Subjects Reporting Changes in Bowel Movements From Baseline (Frequency and/or Consistency) as Recorded in the Diarrhoea Management Diary (DMD)

All subjects completed the baseline DMD during the 3 days prior to randomisation, before any study-related treatment is administered. Subjects randomised to receive Octreotide completed a second baseline DMD before starting the first cycle of treatment with Lapatinib and Capecitabine. The baseline DMD comprised of 3 questions to record stool form and consistency. The DMD to be completed throughout the rest of the study comprised of 3 questions in the baseline DMD and a further 5 questions and 6 sub-questions to evaluate the consequences and management of diarrhoea.

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Reporting Changes in Bowel Movements From Baseline (Frequency and/or Consistency) as Recorded in the Diarrhoea Management Diary (DMD)
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Proportion of Subjects Reporting Changes in Bowel Movements From Baseline (Frequency and/or Consistency) as Recorded in the Diarrhoea Management Diary (DMD)2329
SecondaryTime to the First Subject Reported Change in Frequency and/or Consistency of Bowel Movements From Baseline as Recorded in the DMD

Event is defined as Subjects reporting change in frequency and/or consistency of bowel movements from baseline at least once in DMD. Subject are censored if there is no change in bowel movement frequency/consistency as compared to baseline. Median time and 95% confidence intervals were calculated using Kaplan-Meier estimates.

Time frame:
Up to 24 weeks
Reported as:
Median · Days
Time to the First Subject Reported Change in Frequency and/or Consistency of Bowel Movements From Baseline as Recorded in the DMD
DaysOctreotide TreatmentNo Octreotide Treatment
Time to the First Subject Reported Change in Frequency and/or Consistency of Bowel Movements From Baseline as Recorded in the DMD22.0 (16.0 to 57.0)8.0 (8.0 to 15.0)
SecondaryProportion of Subjects Taking Anti-diarrhoeal Medication as Recorded in the DMD

The proportion of subjects taking medication at least once as a result of diarrhoea are summarised

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Taking Anti-diarrhoeal Medication as Recorded in the DMD
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Proportion of Subjects Taking Anti-diarrhoeal Medication as Recorded in the DMD22
SecondaryProportion of Subjects Making Dietary Changes Due to Diarrhoea as Recorded in the DMD

The proportion of subjects making dietary changes to help with the diarrhoea are summarised

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Making Dietary Changes Due to Diarrhoea as Recorded in the DMD
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Proportion of Subjects Making Dietary Changes Due to Diarrhoea as Recorded in the DMD911
SecondaryProportion of Subjects Contacting Other Non-hospital Healthcare Professionals to Discuss Diarrhoea as Recorded in the DMD

The proportion of subjects contacting a health care professional other than the hospital doctors/nurses to discuss diarrhoea are summarised

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Contacting Other Non-hospital Healthcare Professionals to Discuss Diarrhoea as Recorded in the DMD
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Proportion of Subjects Contacting Other Non-hospital Healthcare Professionals to Discuss Diarrhoea as Recorded in the DMD43
SecondaryProportion of Subjects Reporting Stopping Completely or Missing Doses of Anti-cancer Tablets Due to Diarrhoea as Recorded in the DMD

The proportion of subjects reducing or completely stopping the number of anti-cancer tablets to help with diarrhoea are summarised

Time frame:
Up to 24 weeks
Reported as:
Count of participants · Participants
Proportion of Subjects Reporting Stopping Completely or Missing Doses of Anti-cancer Tablets Due to Diarrhoea as Recorded in the DMD
ParticipantsOctreotide TreatmentNo Octreotide Treatment
Proportion of Subjects Reporting Stopping Completely or Missing Doses of Anti-cancer Tablets Due to Diarrhoea as Recorded in the DMD23

Adverse events

Collected over Up to 28 weeks post randomization (from randomization until up to and including 4 weeks after the last dose of study treatment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Octreotide Treatment1/29 (3.4%)5/29 (17.2%)26/29 (89.7%)
No Octreotide Treatment0/33 (0%)3/33 (9.1%)27/33 (81.8%)
All Patients1/62 (1.6%)8/62 (12.9%)53/62 (85.5%)
Most frequent serious events
Most frequent serious events
EventOctreotide TreatmentNo Octreotide TreatmentAll Patients
DiarrhoeaGastrointestinal disorders1/290/331/62
Lower respiratory tract infectionInfections and infestations1/290/331/62
VulvitisInfections and infestations1/290/331/62
Alanine aminotransferase increasedInvestigations1/290/331/62
ThrombosisVascular disorders1/290/331/62
Osteonecrosis of jawMusculoskeletal and connective tissue disorders0/291/331/62
ParaparesisNervous system disorders0/291/331/62
PneumothoraxRespiratory, thoracic and mediastinal disorders0/291/331/62
Most frequent other events
Showing 10 of 33
Most frequent other events
EventOctreotide TreatmentNo Octreotide TreatmentAll Patients
DiarrhoeaGastrointestinal disorders17/2915/3332/62
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders13/2911/3324/62
AstheniaGeneral disorders2/297/339/62
RashSkin and subcutaneous tissue disorders4/297/3311/62
AnaemiaBlood and lymphatic system disorders1/296/337/62
Alanine aminotransferase increasedInvestigations4/292/336/62
Aspartate aminotransferase increasedInvestigations4/291/335/62
Blood bilirubin increasedInvestigations4/293/337/62
NeutropeniaBlood and lymphatic system disorders1/294/335/62
ThrombocytopeniaBlood and lymphatic system disorders3/293/336/62

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Octreotide TreatmentNo Octreotide TreatmentTotal
Mean57.4 ± 10.0755.9 ± 9.0856.6 ± 9.52
Sex: Female, Male
Sex: Female, Male(Participants)Octreotide TreatmentNo Octreotide TreatmentTotal
Female303262
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Octreotide TreatmentNo Octreotide TreatmentTotal
Hispanic or Latino011
Not Hispanic or Latino303161
09

Study locations

17 sites
  • Novartis Investigative Site
    Olomouc, 775 20, Czechia
  • Novartis Investigative Site
    Tel Aviv, 69710, Israel
  • Novartis Investigative Site
    Gdansk, 80-219, Poland
  • Novartis Investigative Site
    Konin, 62-500, Poland
  • Novartis Investigative Site
    Warszawa, 01-748, Poland
  • Novartis Investigative Site
    Khanty mansiysk, 628012, Russian Federation
  • Novartis Investigative Site
    Moscow, 125367, Russian Federation
  • Novartis Investigative Site
    Nizhniy Novgorod, 603081, Russian Federation
  • Novartis Investigative Site
    Obninsk, 249036, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197758, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 198255, Russian Federation
  • Novartis Investigative Site
    Tomsk, 634050, Russian Federation
  • Novartis Investigative Site
    London, SE5 9RS, United Kingdom
  • Novartis Investigative Site
    Nottingham, NG5 1PB, United Kingdom
  • Novartis Investigative Site
    Plymouth, PL6 8DH, United Kingdom
  • Novartis Investigative Site
    Romford, RM7 0AG, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2014 to primary completion in Oct 2017, 34 months.

Results were first posted in Jul 2019, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2014
First posted
Nov 19, 2014
StartActual
Dec 17, 2014
Primary completionActual
Oct 19, 2017
CompletionActual
Oct 19, 2017
Results first posted
Jul 15, 2019
Last update
Jul 15, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02294786
Responsible party
Sponsor
First posted
Nov 19, 2014
Start date
Dec 17, 2014
Primary completion
Oct 19, 2017
Completion
Oct 19, 2017
Results posted
Jul 15, 2019
Last update
Jul 15, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lapatinib · Capecitabine

Start the discussion